US Bancorp
DSGN icon

US Bancorp’s Design Therapeutics DSGN Stock Holding History

US Bancorp’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$376 Sell
26
-35
-57% -$436 ﹤0.01% 4073
2026
Q1 		$649 Buy
+61
New +$617 ﹤0.01% 3979
2023
Q4 		– Sell
-84
Closed -$198 – 4023
2023
Q3 		$198 Sell
84
-354
-81% -$1.65K ﹤0.01% 3911
2023
Q2 		$2.76K Sell
438
-41
-9% -$251 ﹤0.01% 3622
2023
Q1 		$2.76K Buy
+479
New +$3.58K ﹤0.01% 3685

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

US Bancorp's DSGN Position: Q2 2026 in Review

US Bancorp reduced its Design Therapeutics (DSGN) stake by 57% in Q2 2026, selling an estimated $436 and leaving 26 shares worth $376. The position accounts for ﹤0.01% of the portfolio, ranked #4073.

US Bancorp first reported a position in DSGN in Q1 2023 and has held it in 5 quarters since. The position peaked at $2.76K in Q1 2023. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • US Bancorp held 26 shares of Design Therapeutics worth $376 as of Q2 2026.
  • US Bancorp sold 35 Design Therapeutics shares in Q2 2026, an estimated $436.
  • Design Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #4073 holding.
  • US Bancorp first reported a position in Design Therapeutics in Q1 2023 and has held it in 5 quarters since.
  • US Bancorp's Design Therapeutics position peaked at $2.76K in Q1 2023.
  • 136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.